
Sign up to save your podcasts
Or


At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.
By European Association of Urology3.7
33 ratings
At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC).
Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.

324 Listeners

505 Listeners

58 Listeners

39 Listeners

93 Listeners

83 Listeners

280 Listeners

37 Listeners

58 Listeners

2 Listeners

89 Listeners

55 Listeners

13 Listeners

0 Listeners

14 Listeners